UroGen Pharma (URGN) Treasury Shares (2016 - 2025)

UroGen Pharma (URGN) has reported Treasury Shares for 10 consecutive years, with $1.9 million the latest figure, recorded in Q4 2025.

• Quarterly Treasury Shares rose 27.83% year-over-year to $1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 million (up 27.83% YoY) and the FY2025 annual result came in at $1.9 million, up 27.83% from the prior year.
• Treasury Shares climbed to $1.9 million in Q4 2025 per URGN's latest filing, from $1.5 million in the prior quarter.
• Over the last five years, Treasury Shares for URGN reached as high as $1.9 million in Q4 2025 and fell as low as $690955.0 in Q4 2022.
• A 5-year average of $1.2 million and a median of $1.1 million in 2023 frame the typical range for Treasury Shares.
• Annual changes were most pronounced in 2022 — Treasury Shares slipped 8.27% — and 2023, when it soared 59.01%.
• Year by year, Treasury Shares stood at $753274.0 in 2021, then decreased by 8.27% to $690955.0 in 2022, then jumped by 59.01% to $1.1 million in 2023, then surged by 37.24% to $1.5 million in 2024, then advanced by 27.83% to $1.9 million in 2025.
• According to Business Quant data, Treasury Shares over the past three periods registered $1.9 million, $1.5 million, and $1.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.